Cargando…

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

The decision to administer adjuvant chemotherapy in treatment of early invasive breast cancer (EBC) is often complex, particularly for hormone receptor-positive (HR+) diseases, and current guidelines often classify these patients in an intermediate-risk group. Several biomarkers are currently availa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexandre, Marie, Maran-Gonzalez, Aurélie, Viala, Marie, Firmin, Nelly, D’Hondt, Véronique, Gutowski, Marian, Bourgier, Céline, Jacot, William, Guiu, Séverine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912012/ https://www.ncbi.nlm.nih.gov/pubmed/31849525 http://dx.doi.org/10.2147/CMAR.S221676

Ejemplares similares

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
por: Viala, Marie, et al.
Publicado: (2021)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Corbeau, Ileana, et al.
Publicado: (2020)

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study
por: Fabbro, Michel, et al.
Publicado: (2022)

A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy
por: Chartron, Elodie, et al.
Publicado: (2021)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
por: Corbeau, Iléana, et al.
Publicado: (2020)

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures
por: Bobrie, Angelique, et al.
Publicado: (2022)

How Could Future AI Help Tackle Global Complex Problems?
por: Grisogono, Anne-Marie
Publicado: (2020)

God Help Her
por: McCarroll, James
Publicado: (1892)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

The Dynamic between Self-Efficacy and Emotional Exhaustion through Studyholism: Which Resources Could Be Helpful for University Students?
por: Sanseverino, Domenico, et al.
Publicado: (2023)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Depressive-, Cognitive- or Stroke-Related Risk Factors of Post-Stroke Depression: Which One Could Better Help Clinicians and Patients?
por: Perrain, Rebecca, et al.
Publicado: (2021)

Device could help reveal mysteries of cosmos
Publicado: (2008)

Chimeras could help in the fight against leptospirosis
por: Santos, Jademilson C, et al.
Publicado: (2018)

Could Polyphenols Help in the Control of Rheumatoid Arthritis?
por: Sung, Siyun, et al.
Publicado: (2019)

Immunotherapy could help against new coronavirus
Publicado: (2013)

Could Blockchain Help With COVID-19 Crisis?
Publicado: (2021)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Robust Guidelines for the Management of HR+ Her2− EBC: Crucial Value of CanAssist Breast
por: Vaid, Ashok, et al.
Publicado: (2022)

HR(+)/HER2(−) de novo metastatic breast cancer: a true peculiar entity?
por: Torrisi, Rosalba, et al.
Publicado: (2023)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
por: Jerzak, Katarzyna J., et al.
Publicado: (2023)

Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
por: Wang, Wei, et al.
Publicado: (2023)

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
por: Bordeau, Karl, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qlu4vq0tlv4l4j11dmom34o6o1